{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"With Any TEAE"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"With Any Drug-related TEAE"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"With Any TEAE with an Outcome of Death"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"With Any Serious TEAE"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"With Any Drug-related Serious TEAE"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"With Any Serious TEAE with an Outcome of Death"}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"}],"units":"Participants"}],"groups":[{"description":"KW-0761: In the first treatment course KW-0761 will be administered i.v. once a week for four weeks, followed by a 2-week observation period. Subsequent treatment courses are permissible for subjects demonstrating a response or maintaining stable disease and will consist of an infusion of KW-0761 every other week.","id":"OG000","title":"KW-0761"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"one year","title":"Number of Participants With Adverse Events as a Measure of Safety and Tolerability.","type":"SECONDARY","unitOfMeasure":"Participants"}